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Recent studies have shown a temporal increase in the neutralizing antibody
potency and breadth to SARS-CoV-2 variants in coronavirus disease 2019 (COVID-19)
convalescent individuals. Here, we examined longitudinal antibody responses and viral
neutralizing capacity to the B.1 lineage virus (Wuhan related), to variants of concern
(VOC; Alpha, Beta, Gamma, and Delta), and to a local variant of interest (VOI; Lambda)
in volunteers receiving the Sputnik V vaccine in Argentina. Longitudinal serum samples
(N = 536) collected from 118 volunteers obtained between January and October 2021 were
used. The analysis indicates that while anti-spike IgG levels signiﬁcantly wane over time, the
neutralizing capacity for the Wuhan-related lineages of SARS-CoV-2 and VOC is maintained
within 6 months of vaccination. In addition, an improved antibody cross-neutralizing ability
for circulating variants of concern (Beta and Gamma) was observed over time postvaccination. The viral variants that displayed higher escape to neutralizing antibodies with respect
to the original virus (Beta and Gamma variants) were the ones showing the largest increase
in susceptibility to neutralization over time after vaccination. Our observations indicate that
serum neutralizing antibodies are maintained for at least 6 months and show a reduction
of VOC escape to neutralizing antibodies over time after vaccination.
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IMPORTANCE Vaccines have been produced in record time for SARS-CoV-2, offering the
possibility of halting the global pandemic. However, inequalities in vaccine accessibility in
different regions of the world create a need to increase international cooperation. Sputnik
V is a recombinant adenovirus-based vaccine that has been widely used in Argentina and
other developing countries, but limited information is available about its elicited immune
responses. Here, we examined longitudinal antibody levels and viral neutralizing capacity
elicited by Sputnik V vaccination. Using a cohort of 118 volunteers, we found that while
anti-spike antibodies wane over time, the neutralizing capacity to viral variants of concern
and local variants of interest is maintained within 4 months of vaccination. In addition,
we observed an increased cross-neutralization activity over time for the Beta and Gamma
variants. This study provides valuable information about the immune response generated
by a vaccine platform used in many parts of the world.
KEYWORDS COVID-19, SARS CoV-2, Sputnik V, viral variants

he coronavirus disease 2019 (COVID-19) pandemic is devastating economies and health
care systems worldwide and had caused more than 5 million deaths by November 2021
(1). Mass vaccination offers the possibility of halting this global burden. However, the limited
vaccine supply and inequalities in vaccine accessibility create a need to increase international cooperation. An additional challenge in combatting COVID-19 has been the emergence in late 2020 of new viral variants around the world with greater transmissibility, replication, and/or resistance to neutralizing antibodies. Viral variants harboring mutations in the
spike protein may compromise vaccine immune control, and the rapid spread of these variants could undermine current efforts to end the pandemic. Thus, constant surveillance of viral variant emergence and documentation of immune responses elicited by different vaccine
platforms are fundamental to optimizing pandemic control measures.
The humoral immune response elicited by SARS-CoV-2 infection and vaccination is a
relevant marker of protection against subsequent viral encounters (2–4). Recent reports
have provided important information regarding antibody durability and maturation processes in infected patients (5–7). Antibody titers against SARS-CoV-2 were shown to wane
over time for COVID-19 convalescent individuals, while antibody maturation increased the
neutralization potency to the original SARS-CoV-2 and variants of concern (VOC) (8, 9). This
phenomenon has not been well described for vaccinated individuals.
In this study, we evaluated the humoral response over time and the neutralizing potency
of antibodies elicited by Sputnik V vaccination in Argentina. Sputnik V (Gam-COVID-Vac) has
been extensively used in Argentina and in more than 65 countries around the world. It consists of a two-component heterologous recombinant adenovirus-based vaccine (rAd type 26
and rAd type 5) expressing the spike protein (10, 11). Evaluation of the immune response
over time up to 6 months after vaccination indicates that anti-spike antibody levels wane
but neutralization capacity is maintained not only for the ancestral SARS-CoV-2 but also for
widely and locally circulating viral variants. These data support the notion that antibody afﬁnity maturation and limitation of VOC escape to neutralization occur over time after
Sputnik V vaccination.
RESULTS
We evaluated the longitudinal anti-spike IgG antibody level and viral neutralizing
capacity to SARS-CoV-2 VOC in 118 volunteers (see Table S1 in the supplemental material)
receiving the complete two-dose regimen of the Sputnik V vaccine in Argentina as a continuation of our recent report (12). A collection of 536 serum samples were initially obtained
between January and October 2021. Plasma samples were taken at ﬁve time points: before
vaccination (baseline) and at 21, 42, 120, and 180 days after the initial vaccination (second
dose was applied at 21 days). The levels of IgG antibodies against the complete original
Wuhan spike protein were measured by titration (13), and quantiﬁcation was carried out
using the WHO International Antibody Standard (14). According to the presence of antibodies
at baseline, samples were divided in two groups, without (group 1) or with (group 2) previous
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SARS-CoV-2 infection. Evaluation of infection during the study was assessed by measuring the
presence of IgG antinucleocapsid at 42, 120, and 180 days after Sputnik V vaccination. This
study indicated that 3 individuals were infected during that time. Thus, they were removed
from the analysis. Virus-neutralizing antibodies were evaluated using two systems, a pseudotyped vesicular stomatitis virus (VSV) expressing green ﬂuorescent protein (GFP) (15), carrying
spike from the Wuhan, Alpha (United Kingdom), Beta (South Africa), Gamma (Manaos), and
Delta (India) variants, and the SARS-CoV-2 virus using local isolates for the B.1 lineage (Wuhan
related) and regional circulating SARS-CoV-2 variants (Alpha, Gamma, and Lambda).
Sustained viral neutralization capacity over time upon Sputnik V vaccination. A
longitudinal analysis (N = 536) from 118 volunteers vaccinated with the two-dose regimen
of Sputnik V showed that IgG levels declined over a period of 6 months, but all the samples
analyzed remained seropositive. The geometric mean (GM) international units of IgG antispike antibodies per milliliter (IU/ml) for the group that was seronegative (naive) at baseline
(group 1, N = 88) declined from 732 (95% conﬁdence intervals [95% CI], 552 to 959) at
42 days to 196.9 (95% CI, 149 to 260) and 64 (95% CI, 46 to 90) by 120 and 180 days, respectively, after the initial vaccination (Fig. 1A). IgG level waning was also observed in participants
who were seropositive (due to prior infection) at baseline (group 2; Fig. S1). For this group, the
GM of antibody (IU/ml) was the highest after the ﬁrst dose of the vaccine, 9,429 (95% CI, 6,303
to 14,105), and declined to 5,193 (95% CI, 3,390 to 7,960) and 2,719 (95% CI, 1,706 to 4,333) at
42 and 120 days after the initial vaccination. The geometric mean half-maximal neutralizing titer (GMT IC50) of group 1 samples at 42, 120, and 180 days after the initial vaccination was 112
(95% CI, 80 to 155), 70 (95% CI, 47 to 103), and 44 (95% CI, 26 to 73). (Fig. 1B).
The data show that although the total amount of IgG anti-spike decreases more than 10fold over a period of 6 months after Sputnik V vaccination, the neutralizing capacity in naive
individuals showed only a 2-fold reduction. Analysis of the neutralization index calculated by
dividing the neutralizing titer of each sample by its respective IgG anti-spike concentration
(IU/ml) shows a signiﬁcant index increase as a function of time (Fig. 1C), suggesting a process of antibody maturation during this period.
Reduced VOC escape to neutralization over time after Sputnik V vaccination.
We then evaluated the serum-neutralizing activity for circulating VOC elicited by Sputnik V
vaccination. Viral infection inhibition was assessed using two systems, a VSV-based pseudotyped virus and the isolated SARS-CoV-2. The VSV-based system encoded GFP and was
pseudotyped with the spike protein corresponding to the original SARS-CoV-2 (Wuhan)
and the Alpha (lineage B.1.1.7), Beta (lineage B.1.351), Gamma (lineage P.1), and Delta
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FIG 1 Immune response to the Sputnik V vaccine in naive participants. (A) IgG anti-spike antibody levels quantiﬁed
according to the WHO International Antibody Standard (N = 88). Antibodies were measured 21 (N = 88), 42 (21 days
after second dose) (N = 88), 120 (N = 88), and 180 (N = 64) days after the initial vaccination. (B) Neutralizing titers
measured at 50% inhibition against the pseudotyped virus (CoV2pp GFP) for the same cohort as in panel A. The
geometric means with 95% conﬁdence intervals are shown. Wilcoxon matched-pair test was used. Statistical
signiﬁcance is shown with the following notations: ****, P , 0.0001; ***, P , 0.001; ns, not signiﬁcant. (C) Neutralizing
index calculated at 42, 120, and 180 days after the initial vaccination. The index was deﬁned as the neutralizing titer/
IgG anti-spike measurement for each participant.
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FIG 2 Longitudinal analysis of neutralizing capacities of serum samples from Sputnik-vaccinated participants for each
variant of concern (VOC). Half-maximal neutralizing titers (IC50) against VOC using pseudotyped viruses (CoV2pp GFP),
shown as fold change reduction normalized to the IC50 titer against the original virus (N = 19). Sera collected 42 (A) or
120 (B) days after the initial vaccination were used for neutralization assays with the Alpha, Beta, Gamma, and Delta
variants, as indicated in each case. A Wilcoxon matched-pair test was used to analyze the data shown in panels A and B.
(C) Comparison of fold change neutralization titer decreased for each VOC with respect to the Wuhan virus at 42 and
120 days after vaccination. The Mann-Whitney U test was used. The signiﬁcance of the reduction is indicated on the right.
(D) Neutralizing capacity at 42 and 120 days after initial vaccination for each variant is indicated. For nonpaired samples
analysis in panel D the Mann-Whitney U test was used. Statistical signiﬁcance is shown with the following notations: ****,
P , 0.0001; ***, P , 0.001; *, P , 0.05; ns, not signiﬁcant.

(lineage B.1.617.2) variants, which were initially identiﬁed in the United Kingdom, South Africa,
Manaos, and India, respectively. Serum samples collected 42 days after vaccination showed a
2.5- and 5.1-fold decrease in neutralizing activity against the Alpha and Delta variants compared with the Wuhan-related pseudotyped virus (P = 0.002 and P , 0,0001, respectively)
(Fig. 2A). The samples were less effective at neutralizing the Beta and Gamma variants (19.2and 13.8-fold reduction in neutralizing activity, P , 0.0001 and P , 0.0001, respectively).
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DISCUSSION
Unraveling the long-term kinetics of antibodies to SARS-CoV-2 and VOC in vaccinated
individuals is important for understanding protective immunity against COVID-19 and for
devising effective control measures. Here, we investigated the longitudinal humoral
response in 118 volunteers vaccinated with Sputnik V. Our data indicate that anti-spike IgG
antibodies wane over 6 months after vaccination with a minor loss of serum-neutralizing
capacity against the original SARS-CoV-2 variant. The neutralizing capacity of the antibodies
elicited by the vaccine was slightly or not signiﬁcantly reduced for the Alpha, Lambda, and
Delta variants, while partial escape to neutralization was observed for the Beta and Gamma
variants. Antibodies elicited in individuals vaccinated with the Sputnik V vaccine exhibited
increased cross-neutralization capacity over time to VOC. This might reﬂect the maturation
of the antibody response induced by Sputnik V vaccination. Similar cross-neutralization
increase for the original and VOC viruses was recently observed in longitudinal studies of
individuals previously infected with SARS-CoV-2 (8) and of those harboring cloned neutralizing antibodies derived from convalescent donors (7, 9). These studies suggest that declining
antibody titers are not indicative of declining protection. In summary, our studies support
an increase of cross-neutralization to circulating SARS-CoV-2 variants, reducing the viral
escape to neutralization, in the months following Sputnik V vaccination. Further studies to
evaluate efﬁcacy over time for VOC in vaccinated individuals will be necessary to deﬁne correlates of protection with antibody and neutralization titers.
MATERIALS AND METHODS
Patient and sample origin. This study monitors the humoral immune response over time postimmunization with Sputnik V vaccine in 118 health care workers from Buenos Aires province, Argentina. Patient information
is given in Table S1 in the supplemental material. Blood was collected by venipuncture into SST tubes (BD
Sciences) for serum and stored at 208C.
January/February 2022 Volume 13 Issue 1 e03442-21
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Serum samples collected 120 days after vaccination showed a 2.9-, 9.7-, 4.2-, and
3.4-fold decrease in neutralizing activity against the Alpha, Beta, Gamma, and Delta
variants, respectively, compared with the Wuhan virus (Fig. 2B). Interestingly, a signiﬁcant increase in the relative neutralization capacity was observed over time (from 42 to
120 days after vaccination) for the Beta and Gamma VOC with respect to the Wuhanrelated virus (Fig. 2C). In addition, the level of neutralizing capacities over time was
maintained for all the variants tested (Fig. 2D).
The Lambda variant was initially detected in late December 2020 in South America
(Andina, lineage C.37) (16). This novel sublineage within B.1.1.1, with a convergent deletion in the ORF1a gene (D3675–3677) and a novel deletion in the spike gene (D246–252,
G75V, T76I, L452Q, F490S, T859N), rapidly spread in the region, replacing the Alpha variant
and reaching frequencies in Argentina as high as 48% (17). The Lambda, Alpha, and Gamma
variants are the main SARS-CoV-2 viruses currently circulating in Argentina. The antibodyneutralizing activity elicited by the Sputnik V vaccine was analyzed using the original local
isolate B.1 (Wuhan related) virus and local isolates of the viral variants. A subset of 40 randomly selected group 1 volunteers was used for this analysis. Neutralizing titers were
deﬁned as the highest serum dilution that failed to elicit a cytopathic effect (CPE) on the cell
monolayer (Fig. 3). Each sample is indicated with a dot, and the multiple lines in one dot correspond to different samples with the same neutralization titer.
The virus-neutralizing capacity of serum from Sputnik V-vaccinated individuals was
slightly lower for the Lambda variant than for the original B.1 virus (2.8- and 2.9-fold change at
42 and 120 days after the ﬁrst vaccination dose, respectively). For the Alpha variant, no signiﬁcant (at 42 days after the ﬁrst dose) or mild (at 120 days after the ﬁrst dose) escape to neutralization was observed (Fig. 3A and B). In contrast, sera from vaccinated volunteers were less
effective against the Gamma variant, showing a 5.9- and 2.9-fold reduction of inhibition in
samples collected at 42 and 120 days after the initial vaccination, respectively (Fig. 3C).
Neutralization capacity was maintained over time after Sputnik V vaccination for all SARSCoV-2 variants analyzed (Fig. 3D). Together, these data suggest an improved cross-neutralization capacity, limiting VOC antibody escape to neutralization over time after vaccination.

®

FIG 3 Longitudinal analysis of the neutralizing capacities of sera from Sputnik V-vaccinated individuals for each variant of
concern (VOC) using viral isolates circulating in Argentina. The neutralizing titer (IC90) for VOC using a replicating SARSCoV-2 was assessed and shown as fold change reduction with respect to that for the original B.1 virus. Neutralizing titers
were deﬁned as the highest serum dilution without any cytopathic effect on the monolayer. Sera (N = 40) collected
42 days (A) or 120 days (B) after initial immunization were used for neutralization assays with Alpha, Gamma, and
Lambda variants, as indicated in each case. Each sample in panels A and B is indicated with a dot, and the multiple lines
from one dot correspond to different samples with the same neutralization titer. Wilcoxon matched-pair test was used in
panels A and B. (C) Comparison of fold change neutralization titer decrease for each VOC with respect to the original B.1
virus at 42 and 120 days after vaccination. The Mann-Whitney U test was used. The signiﬁcance of the reduction is
indicated on the right. (D) Neutralizing capacity calculated at 42 and 120 days after initial immunization is shown for each
variant. For nonpaired samples analysis in panel D the Mann-Whitney U test was used. Statistical signiﬁcance is shown
with the following notations: ****, P , 0.0001; ***, P , 0.001; *, P , 0.05; ns, not signiﬁcant.

Ethics. Study enrollment started in January 2021 and is ongoing. Ethical approval was obtained
from the central committee of the Ministry of Health of Buenos Aires, and all participants provided written informed consent prior to collection of data and specimens (Cod#2021-00983502). All specimens
were deidentiﬁed prior to processing and antibody testing for all serum specimens.
Cohort description. The cohort was 31.4% male and 68.6% female, with an average age of 49.3 years
(range, 22 to 76 years). Information about ethnicity was not collected.
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Sequential serum samples were collected at ﬁve time points, before vaccination (baseline) and at 21,
42, 120, and 180 days after the initial vaccination starting in January 2021. Volunteers were divided into two
groups: without (group 1) or with (group 2) previous SARS-CoV-2 infection. Volunteers were classiﬁed according to the result of an enzyme-linked immunosorbent assay (ELISA) IgG anti-spike test at baseline.
Cell lines. Vero-CCL81 cells (ATCC) and 293T ACE2/TMPRSS2 cells (kindly provided by Benhur Lee)
were used. Cells were cultured at 37°C in 5% CO2 in Dulbecco’s modiﬁed Eagle’s high-glucose medium
(Thermo Fisher Scientiﬁc) supplemented with 10% fetal bovine serum (FBS) (GIBCO).
Viruses. SARS-CoV-2 pseudotyped particles (CoV2pp-GFP) expressing spike protein were generated
in the Sean Whelan laboratory. The S gene of SARS-CoV-2 isolate Wuhan-Hu-1 (GenBank accession no.
MN908947.3) and pseudotyped VSVs expressing variants of the SARS-CoV-2 spike, including B.1.1.7 (GenBank
accession no. OU117158.1), B.1.351 (GenBank accession no. MZ212516.1), and P.1 (GISAID EPI_ISL_804823), were
generated (15).
The B.1, Alpha (B.1.1.7), Gamma (P.1), and Lambda (C.37) isolates were obtained from nasopharyngeal isolates. All viruses were passaged only once in Vero cells. To conﬁrm the substitutions of the respective variant
and to evaluate stability during the passage, the whole genome was subjected to deep sequencing using an
Illumina platform. All virus experiments were performed in approved biosafety level 3 facilities.
SARS-CoV-2 pseudotyped VSV. Brieﬂy, pseudotyped VSVs were rescued by infecting BSRT7/5 cells
with vaccinia virus vTF7-3 and subsequently transfecting them with T7-driven support plasmids encoding VSV N, P, L, G, and VSV genomic cDNAs. Supernatants were harvested 72 h postinfection, cellular debris was removed by centrifugation (5 min and 1,000  g), and supernatants were passed through 0.22m m ﬁlters. Supernatants were plaque puriﬁed on Vero-CCL81 cells. Individual clones were grown on
Vero-CCL81 cells to generate P1 stocks. Working stocks were generated on Vero-CCL81 cells at 34°C.
Viral stocks (VSV-eGFP-SARS-CoV-2), generated in the Sean Whelan laboratory, were ampliﬁed in our laboratory using 293T ACE2/TMPRSS2 cells at an MOI of 0.01 in Dulbecco’s modiﬁed Eagle’s medium containing 2% FBS at 37°C. Viral supernatants were harvested upon extensive CPE and GFP-positive cells.
The medium was clariﬁed by centrifugation at 1,000  g for 5 min. Viral stocks were titrated by ﬂuorescence-forming units per milliliter (FFU/ml) in the Vero cell line. Aliquots were maintained at 280°C.
SARS-CoV-2. SARS-CoV-2 ancestral reference strain 2019 (GISAID accession ID EPI_ISL_499083) B.1
was obtained from Sandra Gallegos (InViV working group). Alpha (GISAID accession ID EPI_ISL_2756558)
and Gamma (GISAID accession ID EPI_ISL_2756556) variants were isolated at INBIRS from nasopharyngeal
swabs. Lambda (hCoV-19/Argentina/PAIS-A0612/2021; GISAID accession ID EPI_ISL_3320903) variant was isolated at INBIRS from a sample of nasopharyngeal swab kindly transferred by M. Viegas and P. Pais. Virus was
ampliﬁed in Vero E6 cells, and viral stock identity was conﬁrmed by whole-genome sequencing in an Illumina
sequencer. Nucleic acid sequence for each viral stock was uploaded to GISAID and completely matched reference sequences for each variant, discarding acquisition of mutations during isolation and ampliﬁcation processes. Work with SARS-CoV-2 was approved by the INBIRS Institutional Biosafety Committee at biosafety level 3
with negative pressure.
Sequencing of the S gene. Viral RNA was extracted from VSV-SARS-CoV-2 mutant viruses using
TRIzol LS reagent (Thermo Fisher Scientiﬁc), and S was ampliﬁed using M-MLV reverse transcriptase
(Thermo Fisher Scientiﬁc). The mutations were identiﬁed by Sanger sequencing (Applied Biosystems).
SARS-CoV-2 antibody ELISA. Antibodies to SARS-CoV-2 spike protein were detected using an
established commercially available two-step ELISA (COVIDAR). We have previously described the development of the ELISA (13). Brieﬂy, the assay uses plates coated with a mixture of spike and the receptor
binding domain (RBD). The viral proteins were puriﬁed from transfected FreeStyle 293-F suspension cells
using HisTrap excel columns. The conjugated monoclonal antibody used for human IgG detection in the
COVIDAR ELISA is G18-145, which speciﬁcally binds to the heavy chain of all four human immunoglobulin G subclasses: IgG1, IgG2, IgG3, and IgG4.
The IgG concentration of each sample, expressed in international units per milliliter (14), was calculated by
extrapolation of the optical density at 450 nm (OD450) on a calibration curve. For construction of the calibration
curve, we determined the OD450 of serial dilutions of the WHO International Standard for anti-SARS-CoV-2 immunoglobulin. The linear range used was an OD450 of 0.2 to 1.5. Therefore, we performed serial dilutions of the
samples to ﬁnd conditions where the OD450 of each sample ﬁt adequately in the linear range.
SARS-CoV-2 spike pseudotyped VSV neutralization assay. To compare the neutralizing activity of
volunteer’s sera against coronaviruses, neutralization assays were carried out with SARS-CoV-2 pseudotyped particles (CoV2pp-GFP), generated in the Sean Whelan laboratory (15). CoV2pp-GFP carries vesicular stomatitis virus as the viral backbone, and the glycoprotein gene (G) was replaced with the full-length wildtype or VOC spike protein of SARS-CoV-2 (VSV-eGFP-SARS-CoV-2). Vero cells were used for these assays. Cells
were maintained with Dulbecco’s modiﬁed Eagle’s medium (DMEM) high glucose with 10% FBS and were
seeded in a 96-well plate the day before infection. Patient sera were heat inactivated at 56°C for 30 min and
serially diluted in DMEM high-glucose medium. Serum neutralizations were performed by ﬁrst diluting the
inactivated sample 2-fold and continuing with a 2-fold serial dilution. A pretitrated amount of pseudotyped
particles was incubated with a 2-fold serial dilution of patient sera for 1 h at 37°C prior to infection.
Subsequently, cells were ﬁxed in 4% formaldehyde containing 2 mg/ml 49,6-diamidino-2-phenylindole (DAPI)
nuclear stain (Invitrogen) for 1 h at room temperature, and ﬁxative was replaced with PBS. Images were
acquired with the InCell 2000 Analyzer (GE Healthcare) automated microscope in both the DAPI and ﬂuorescein isothiocyanate (FITC) channels to visualize nuclei and infected cells (i.e., eGFP-positive cells), respectively
(4 objective, 4 ﬁelds per well, covering the entire well). Images were analyzed using the multitarget analysis
module of the InCell Analyzer 2000 workstation software (GE Healthcare). GFP-positive cells were identiﬁed in
the FITC channel using the top-hat segmentation method and subsequently counted within the InCell
Workstation software. Absolute inhibitory concentration (absIC) values were calculated for all patient serum
January/February 2022 Volume 13 Issue 1 e03442-21
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samples by modeling a 4-parameter logistic (4PL) regression with GraphPad Prism 8. The 4PL model describes
the sigmoid-shaped response pattern. For clarity, it is assumed that the response can be expressed so that the
slope increases as the concentration increase. absIC was calculated as the corresponding point between the 0%
and 100% assay controls. Fifty percent inhibition was deﬁned by the controls for all samples on the same plate.
For example, the absIC50 would be the point at which the curve matches inhibition equal to exactly 50% of the
100% assay control relative to the assay minimum. A 4PL regression with GraphPad Prism 8 was used.
SARS-CoV-2 neutralization assay. Serum samples were heat inactivated at 56°C for 30 min and serial dilutions from 1/2 to 1/8,192 were incubated for 1 h at 37°C in the presence of ancestral or variants
of SARS-CoV-2 in DMEM, 2% FBS. Fifty microliters of the mixture was then deposited over Vero cell
monolayers for an hour at 37°C (MOI, 0.01). Infectious medium was removed and replaced for DMEM, 2% FBS.
After 72 h, cells were ﬁxed with 4% paraformaldehyde (4°C, 20 min) and stained with crystal violet solution in
methanol. The CPE of the virus on the cell monolayer was assessed visually. If even minor damage to the monolayer was observed in the well, the well was considered a well with a manifestation of CPE. Neutralization titer
was deﬁned as the highest serum dilution without any CPE in two of three replicable wells.
Quantiﬁcation and statistical analysis. Antibody concentration, neutralizing titer, and neutralizing
potency index from volunteers of the same group were analyzed collectively. Neutralization assays were
performed in biological duplicates.
All statistical tests and plots were performed using GraphPad Prism 8.0 software. Comparison on
nonpaired determinations of antibody concentration and neutralizing titer were made using two-tailed
Mann-Whitney U test in Fig. 2C and D and 3C and D. Comparisons of antibody concentration and neutralizing titer were made using two-tailed Wilcoxon matched-pair test in Fig. 1A and B, 2A and B, and 3A
and B and Fig. S1. Statistical signiﬁcance is shown in the ﬁgure legends with the following notations:
****, P , 0.0001; ***, P , 0.001; **, P , 0.01; *, P , 0.05; ns, not signiﬁcant. Geometric means with 95%
conﬁdence intervals were calculated for Fig. 1A and B, 2A and B, and 3A and B and Fig. S1.
Data availability. The data sets generated and/or analyzed during the current study are available in
the Mendeley Data repository at https://doi.org/10.17632/v2ksr58dcv.1.
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